Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol pravastatin/aspirin co-package

Executive Summary

Bristol-Myers Squibb's NDA (21-387) for a pravastatin/aspirin co-package (tentatively named Pravaguard) will return to FDA's Cardiovascular & Renal Drugs Advisory Committee for consideration on the afternoon of July 18. The NDA was resubmitted following a Jan. 18 meeting at which the committee voted against approval for long-term management to reduce the risk of cardiovascular events in patients with clinically evident coronary heart disease (1"The Pink Sheet" Jan. 21, p. 7)...

You may also be interested in...

Pravachol/Aspirin Fixed-Dose Inflexibility May Lead To Undertreatment

Bristol-Myers Squibb's Pravachol/Bufferin titration inflexibility was cited as a main issue by FDA's Cardiovascular & Renal Drugs Advisory Committee in voting against approval of the fixed-dose combination of the cholesterol-lowering and aspirin products

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia

Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts